- Home
- INR vs IOVA Comparison
INR vs IOVA Comparison
Compare INR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- IOVA
- Stock Information
- Founded
- INR 2017
- IOVA 2007
- Country
- INR United States
- IOVA United States
- Employees
- INR N/A
- IOVA N/A
- Industry
- INR
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INR
- IOVA Health Care
- Exchange
- INR NYSE
- IOVA Nasdaq
- Market Cap
- INR 295.3M
- IOVA 771.4M
- IPO Year
- INR 2025
- IOVA N/A
- Fundamental
- Price
- INR $15.08
- IOVA $1.93
- Analyst Decision
- INR Strong Buy
- IOVA Buy
- Analyst Count
- INR 7
- IOVA 10
- Target Price
- INR $26.86
- IOVA $12.22
- AVG Volume (30 Days)
- INR 403.5K
- IOVA 12.1M
- Earning Date
- INR 08-11-2025
- IOVA 08-07-2025
- Dividend Yield
- INR N/A
- IOVA N/A
- EPS Growth
- INR N/A
- IOVA N/A
- EPS
- INR 1.89
- IOVA N/A
- Revenue
- INR $293,962,000.00
- IOVA $212,679,000.00
- Revenue This Year
- INR $49.25
- IOVA $86.62
- Revenue Next Year
- INR $19.77
- IOVA $69.95
- P/E Ratio
- INR $8.11
- IOVA N/A
- Revenue Growth
- INR 62.18
- IOVA 11070.12
- 52 Week Low
- INR $13.64
- IOVA $1.64
- 52 Week High
- INR $23.00
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- INR N/A
- IOVA 43.71
- Support Level
- INR N/A
- IOVA $1.85
- Resistance Level
- INR N/A
- IOVA $2.15
- Average True Range (ATR)
- INR 0.00
- IOVA 0.12
- MACD
- INR 0.00
- IOVA 0.03
- Stochastic Oscillator
- INR 0.00
- IOVA 22.67
About INR INFINITY NATURAL RESOURCES INC
Infinity Natural Resources Inc is an oil and natural gas exploration and production company. The group focused on developing unconventional reserves in Appalachia. The company is engaged in acquiring, exploring, producing, and developing properties for producing oil, natural gas, and natural gas liquids (NGLs) from underground reservoirs.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.